Ozempic vs Wegovy: how they compare
Ozempic is a glp-1 receptor agonist; Wegovy is a glp-1 receptor agonist. The right choice is a clinical decision based on your history, tolerance and goals — not a universal ranking. Trial averages differ, but individual response varies widely.
Side-by-side
Highest-dose trial averages, different trials and populations — a directional comparison, not a head-to-head. Individual results vary and are not guaranteed.
| Factor | Ozempic | Wegovy |
|---|---|---|
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Brands | Ozempic and Rybelsus (type 2 diabetes), Wegovy (chronic weight management) | Ozempic and Rybelsus (type 2 diabetes), Wegovy (chronic weight management) |
| FDA status | FDA-approved as a finished drug under the brand names above. | FDA-approved as a finished drug under the brand names above. |
Ozempic
Semaglutide is a GLP-1 receptor agonist that lowers blood sugar and reduces appetite by mimicking the incretin hormone GLP-1. It is FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. In trials, weight-management dosing produced roughly 15% average body-weight reduction over 68 weeks.
Wegovy
Semaglutide is a GLP-1 receptor agonist that lowers blood sugar and reduces appetite by mimicking the incretin hormone GLP-1. It is FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. In trials, weight-management dosing produced roughly 15% average body-weight reduction over 68 weeks.
Frequently asked questions
Is Ozempic or Wegovy more effective for weight loss?
Trial averages differ by molecule and dose, but head-to-head results do not translate to any one person's outcome. Effectiveness, tolerability and eligibility are individual. See the ozempic and wegovy guides.
Sources
- U.S. Food and Drug Administration — labels for both molecules.
- Pivotal trials as cited in each drug guide.